Evidence memo

KPV

Also tracked as: Lysine-proline-valine, alpha-MSH fragment

A small anti-inflammatory peptide with mechanistic gut and inflammation interest, but no strong human outcome base.

Preclinical Safety watch

Evidence status

High interest / low certainty. Evidence level: Preclinical.

Whether anti-inflammatory mechanisms in models translate into meaningful human disease outcomes.

Gut-inflammation and barrier claims are common, and the mechanism is easy to oversimplify.

Mostly preclinical and mechanistic literature. Human therapeutic evidence remains the gap.

Human efficacy, safety, product identity, and which indication would be plausible enough to test.

Preclinical anti-inflammatory effects should not be converted into treatment claims.

Registered human studies, clinically relevant endpoints, and regulatory clarity.

Mechanistically interesting, clinically unproven.

PubMed

Dalmasso et al. · 2008

Preclinical/mechanistic anti-inflammatory context.

FDA

U.S. Food and Drug Administration · Current FDA page

Regulatory source for compounding-safety watch items; status should be rechecked before publication.